218 related articles for article (PubMed ID: 33244501)
1. DIABETIC KETOACIDOSIS ASSOCIATED WITH ALPELISIB TREATMENT OF METASTATIC BREAST CANCER.
Farah SJ; Masri N; Ghanem H; Azar M
AACE Clin Case Rep; 2020; 6(6):e349-e351. PubMed ID: 33244501
[TBL] [Abstract][Full Text] [Related]
2. Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer.
Abufaied M; Jumbo U; Alqalalwah A; Hamad MK
Cureus; 2021 Nov; 13(11):e19441. PubMed ID: 34909343
[TBL] [Abstract][Full Text] [Related]
3. Diabetic Ketoacidosis With the Use of Alpelisib in a Patient With Metastatic Breast Cancer Without Diabetes.
Polisetty L; Teresa Selvin S; Tan JW
JCEM Case Rep; 2024 Apr; 2(4):luae023. PubMed ID: 38524964
[TBL] [Abstract][Full Text] [Related]
4. Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature.
Carrillo M; Rodriguez RM; Walsh CL; Mcgarvey M
AACE Clin Case Rep; 2021; 7(2):127-131. PubMed ID: 34095470
[TBL] [Abstract][Full Text] [Related]
5. Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer.
Al Zeyoudi J; El Kebbi I; Al Zaabi F; Hashmi S
Cureus; 2021 Dec; 13(12):e20817. PubMed ID: 35141074
[TBL] [Abstract][Full Text] [Related]
6. Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Learnings and Observations Regarding Alpelisib Initiation and Rechallenge.
Leung M; Rodrigues P; Roitman D
Onco Targets Ther; 2022; 15():1309-1315. PubMed ID: 36330532
[TBL] [Abstract][Full Text] [Related]
7. Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient.
Fugere T; Roy AM; Makhoul I
Cureus; 2021 Nov; 13(11):e19295. PubMed ID: 34900474
[TBL] [Abstract][Full Text] [Related]
8. Alpelisib-Induced Diabetic Ketoacidosis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and Review of the Literature.
Ziegengeist JL; Elmes JB; Strassels SA; Patel JN; Moore DC
Clin Breast Cancer; 2024 Jun; 24(4):e204-e209. PubMed ID: 38245400
[TBL] [Abstract][Full Text] [Related]
9. S.U.G.A.R: A Case to Outline Tactics for the Prevention of Alpelisib-Induced Hyperglycemia.
Thomas K; Germain M; Loch MM
J Investig Med High Impact Case Rep; 2022; 10():23247096221105249. PubMed ID: 35712858
[TBL] [Abstract][Full Text] [Related]
10. Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations.
Pla Peris B; Arranz Martin A; Ballesteros García A; Sebastián-Valles F; Marazuela Azpiroz M
Front Endocrinol (Lausanne); 2022; 13():802612. PubMed ID: 35178031
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose cotransporter-2 inhibitors for hypergycemia in phosphoinositide 3-kinase pathway inhibition.
Weintraub MA; Liu D; DeMatteo R; Goncalves MD; Flory JH
Breast Cancer Res Treat; 2024 Jan; 203(1):85-93. PubMed ID: 37704834
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin-associated diabetic ketoacidosis: a case report.
Köksalan D; Sözen M; Selek A; Gezer E; Cantürk Z; Çetinarslan B
Int J Diabetes Dev Ctries; 2023 Feb; 43(1):120-124. PubMed ID: 35875342
[TBL] [Abstract][Full Text] [Related]
13. Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.
Tankova T; Senkus E; Beloyartseva M; Borštnar S; Catrinoiu D; Frolova M; Hegmane A; Janež A; Krnić M; Lengyel Z; Marcou Y; Mazilu L; Mrinakova B; Percik R; Petrakova K; Rubovszky G; Tokar M; Vrdoljak E
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406370
[TBL] [Abstract][Full Text] [Related]
14. Alpelisib-Induced Diabetic Ketoacidosis.
Nguyen P; Musa A; Samantray J
Cureus; 2021 May; 13(5):e14796. PubMed ID: 34084688
[TBL] [Abstract][Full Text] [Related]
15. A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma.
Wu L; Li B
Diabetes Metab Syndr Obes; 2021; 14():753-757. PubMed ID: 33628041
[TBL] [Abstract][Full Text] [Related]
16. Euglycemic Diabetic Ketoacidosis, a Misleading Presentation of Diabetic Ketoacidosis.
Thawabi M; Studyvin S
N Am J Med Sci; 2015 Jun; 7(6):291-4. PubMed ID: 26199928
[TBL] [Abstract][Full Text] [Related]
17. Diabetic ketoacidosis, hyperuricemia and encephalopathy intractable to regular-dose insulin.
Gregory J; Basu S
J Pediatr Endocrinol Metab; 2017 Nov; 30(12):1317-1320. PubMed ID: 29127768
[TBL] [Abstract][Full Text] [Related]
18. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
Diaz-Ramos A; Eilbert W; Marquez D
Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
[TBL] [Abstract][Full Text] [Related]
19. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
Hakami OA; Ioana J; Ahmad S; Tun TK; Sreenan S; McDermott JH
Endocrinol Diabetes Metab Case Rep; 2019 Mar; 2019():. PubMed ID: 30836329
[TBL] [Abstract][Full Text] [Related]
20. Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer.
Shen S; Chen Y; Carpio A; Chang C; Iyengar NM
Cancer; 2023 Dec; 129(24):3854-3861. PubMed ID: 37743730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
